No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AURA250117C5000
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover267.63%IV-34.21%PremiumJan 17, 2025Expiry Date2.60Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9147Delta0.0585Gamma2.79Leverage Ratio-0.0330Theta0.0007Rho2.55Eff Leverage0.0016Vega
Intraday
- 5D
- Daily
No Data
News
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket
Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
BTIG Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24
Scotiabank Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23
Aura Biosciences Analyst Ratings